RecruitingEarly Phase 1NCT07126782
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Intervention
- Ex-vivo expanded allogeneic γδ T cells(biological)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Institute of Hematology & Blood Diseases Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07126782 on ClinicalTrials.govOther trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548710Study of SA+X in the Treatment of Newly Diagnosed AMLRuijin Hospital
- RECRUITINGNANCT07183878Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)First Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT04010877Multiple CAR-T Cell Therapy Targeting AMLShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE1, PHASE2NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantBenjamin Tomlinson
- RECRUITINGPHASE1, PHASE2NCT03222674Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaShenzhen Geno-Immune Medical Institute
- RECRUITINGNCT06513273Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)Gruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseYehui Tan
- RECRUITINGPHASE1NCT07011004A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous LeukemiaMemorial Sloan Kettering Cancer Center
See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) →